PMID- 22567368 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20120823 LR - 20211021 IS - 2090-3162 (Electronic) IS - 2090-3154 (Print) IS - 2090-3162 (Linking) VI - 2011 DP - 2011 TI - Genetic markers used for risk stratification in multiple myeloma. PG - 798089 LID - 10.4061/2011/798089 [doi] LID - 798089 AB - While no specific genetic markers are required in the diagnosis of multiple myeloma (MM), multiple genetic abnormalities and gene signatures are used in disease prognostication and risk stratification. This is particularly important for the adequate identification of the high-risk MM group, which does not benefit from any of the current therapies, and novel approaches need to be proposed. Fluorescence in situ hybridization (FISH) has been employed for establishing risk-based stratification and still remains the most used genetic technique in the clinical routine. The incorporation of gene expression profiling (GEP) in the study of MM has shown to be a very powerful test in the patient stratification, but its incorporation in clinical routine depends on some technical and logistic resolutions. Thus, FISH still remains the gold standard test for detecting genomic abnormalities and outcome discrimination in MM. FAU - Segges, Priscilla AU - Segges P AD - Laboratory of Molecular Biology, Bone Marrow Transplantation Center, National Cancer Institute, Rio de Janeiro, RJ 20230-130, Brazil. FAU - Braggio, Esteban AU - Braggio E LA - eng PT - Journal Article DEP - 20110913 PL - Egypt TA - Genet Res Int JT - Genetics research international JID - 101571472 PMC - PMC3335595 EDAT- 2011/01/01 00:00 MHDA- 2011/01/01 00:01 PMCR- 2011/09/13 CRDT- 2012/05/09 06:00 PHST- 2011/05/31 00:00 [received] PHST- 2011/07/14 00:00 [accepted] PHST- 2012/05/09 06:00 [entrez] PHST- 2011/01/01 00:00 [pubmed] PHST- 2011/01/01 00:01 [medline] PHST- 2011/09/13 00:00 [pmc-release] AID - 10.4061/2011/798089 [doi] PST - ppublish SO - Genet Res Int. 2011;2011:798089. doi: 10.4061/2011/798089. Epub 2011 Sep 13.